Clinical Research Directory
Browse clinical research sites, groups, and studies.
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Sponsor: Fudan University
Summary
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Official title: A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2026-01-28
Completion Date
2029-01-31
Last Updated
2026-03-03
Healthy Volunteers
No
Conditions
Interventions
tunlametinib
Tunlametinib will be administered at a dose of 12 mg orally, twice daily, continuously, in 4-week treatment cycles. Study treatment will continue until the occurrence of intolerable toxicity, PD, withdrawal of consent, initiation of new anti-tumor therapy, death, or when the investigator judges the risk outweighs the benefit, or the study is terminated/ends (whichever occurs first).
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China